ES2281409T3 - Expresion heterologa de proteinas de neisseria. - Google Patents

Expresion heterologa de proteinas de neisseria. Download PDF

Info

Publication number
ES2281409T3
ES2281409T3 ES01914109T ES01914109T ES2281409T3 ES 2281409 T3 ES2281409 T3 ES 2281409T3 ES 01914109 T ES01914109 T ES 01914109T ES 01914109 T ES01914109 T ES 01914109T ES 2281409 T3 ES2281409 T3 ES 2281409T3
Authority
ES
Spain
Prior art keywords
baselineskip
dddseqskip
hskip
hfill
artificial sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES01914109T
Other languages
English (en)
Spanish (es)
Inventor
Maria Beatrice c/o Chiron SpA ARICO
Maurizio c/o Chiron SpA COMANDUCCI
Cesira c/o Chiron SpA GALEOTTI
Vega c/o Chiron SpA MASIGNANI
Marzia Monica c/o Chiron SpA GUILIANI
Mariagrazia c/o Chiron SpA PIZZA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GSK Vaccines SRL
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics SRL
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243750&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2281409(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0004695A external-priority patent/GB0004695D0/en
Priority claimed from GB0027675A external-priority patent/GB0027675D0/en
Application filed by Novartis Vaccines and Diagnostics SRL, Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics SRL
Application granted granted Critical
Publication of ES2281409T3 publication Critical patent/ES2281409T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES01914109T 2000-02-28 2001-02-28 Expresion heterologa de proteinas de neisseria. Expired - Lifetime ES2281409T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0004695A GB0004695D0 (en) 2000-02-28 2000-02-28 Protein expression
GB0004695 2000-02-28
GB0027675A GB0027675D0 (en) 2000-11-13 2000-11-13 Protein Expression
GB0027675 2000-11-13

Publications (1)

Publication Number Publication Date
ES2281409T3 true ES2281409T3 (es) 2007-10-01

Family

ID=26243750

Family Applications (5)

Application Number Title Priority Date Filing Date
ES01914109T Expired - Lifetime ES2281409T3 (es) 2000-02-28 2001-02-28 Expresion heterologa de proteinas de neisseria.
ES10178586T Expired - Lifetime ES2386534T3 (es) 2000-02-28 2001-02-28 Expresión heteróloga de proteínas de Neisseria
ES06076718T Expired - Lifetime ES2391153T3 (es) 2000-02-28 2001-02-28 Expresión heteróloga de proteínas de Neisseria
ES08075111T Expired - Lifetime ES2360746T3 (es) 2000-02-28 2001-02-28 Expresión híbrida de proteínas e neisseriales.
ES01914098T Expired - Lifetime ES2299476T3 (es) 2000-02-28 2001-02-28 Expresion hibrida de proteinas de neisseria.

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES10178586T Expired - Lifetime ES2386534T3 (es) 2000-02-28 2001-02-28 Expresión heteróloga de proteínas de Neisseria
ES06076718T Expired - Lifetime ES2391153T3 (es) 2000-02-28 2001-02-28 Expresión heteróloga de proteínas de Neisseria
ES08075111T Expired - Lifetime ES2360746T3 (es) 2000-02-28 2001-02-28 Expresión híbrida de proteínas e neisseriales.
ES01914098T Expired - Lifetime ES2299476T3 (es) 2000-02-28 2001-02-28 Expresion hibrida de proteinas de neisseria.

Country Status (19)

Country Link
US (9) US20040092711A1 (https=)
EP (6) EP2270030B1 (https=)
JP (8) JP4846160B2 (https=)
CN (7) CN100339482C (https=)
AT (3) ATE352631T1 (https=)
AU (4) AU2001239478B2 (https=)
BR (2) BR0108711A (https=)
CA (5) CA2875231A1 (https=)
CY (6) CY1106532T1 (https=)
DE (3) DE60132978T2 (https=)
DK (4) DK1790660T3 (https=)
ES (5) ES2281409T3 (https=)
LU (1) LU92240I2 (https=)
MX (2) MXPA02008313A (https=)
NL (1) NL300605I2 (https=)
NZ (2) NZ521531A (https=)
PT (4) PT1790660E (https=)
RU (2) RU2304617C2 (https=)
WO (2) WO2001064920A2 (https=)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298900A1 (en) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Compositions and methods for treating intracellular diseases
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
EP2270173B1 (en) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
RU2281956C2 (ru) 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
PT2289545T (pt) * 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US6928463B1 (en) * 2001-07-06 2005-08-09 Nortel Networks Limited Broadband content delivery via personal content tunnel
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
AU2014201962B2 (en) * 2001-09-06 2016-06-09 Glaxosmithkline Vaccines S.R.L. Hybrid and tandem expression of Neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US7838015B2 (en) 2001-10-03 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Adjuvanted meningococcus compositions
CN100354297C (zh) * 2001-10-03 2007-12-12 希龙公司 辅助的脑膜炎球菌组合物
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
EP1524991A1 (en) * 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
EP2395073B1 (en) 2002-11-01 2017-09-06 GlaxoSmithKline Biologicals S.A. Drying process
EP1562982B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics S.r.l. Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
WO2005019265A1 (en) 2003-08-13 2005-03-03 Chiron Corporation Improved method of purifying tfpi and tfpi analogs
CN103357002A (zh) 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0419408D0 (en) * 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
AU2006214064B2 (en) 2005-02-18 2012-04-26 J. Craig Venter Institute, Inc. Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ599345A (en) 2005-02-18 2013-07-26 Novartis Vaccines & Diagnostic Immunogens from uropathogenic Escherichia Coli
CN100475965C (zh) * 2005-07-22 2009-04-08 上海高科联合生物技术研发有限公司 一种大肠杆菌高效外分泌表达溶葡萄球菌酶的方法
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2007066226A2 (en) * 2005-12-06 2007-06-14 Universita Degli Studi Di Padova Methods and compositions relating to adhesins as adjuvants
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
RU2360926C9 (ru) * 2008-03-17 2009-09-10 Всеволод Иванович Киселев ГИБРИДНЫЙ БЕЛОК CFP10-ESAT6, ИНДУЦИРУЮЩИЙ РЕАКЦИЮ ГИПЕРЧУВСТВИТЕЛЬНОСТИ ЗАМЕДЛЕННОГО ТИПА В ОТНОШЕНИИ M.Tuberculosis, КОДИРУЮЩАЯ ЕГО ХИМЕРНАЯ НУКЛЕИНОВАЯ КИСЛОТА И РЕКОМБИНАНТНЫЙ ПЛАЗМИДНЫЙ ЭКСПРЕССИРУЮЩИЙ ВЕКТОР, ЕЕ СОДЕРЖАЩИЙ, СПОСОБ ПОЛУЧЕНИЯ ГИБРИДНОГО БЕЛКА И ДОЗИРОВАННАЯ ЛЕКАРСТВЕННАЯ ФОРМА ДЛЯ ВНУТРИКОЖНОЙ ИНЪЕКЦИИ НА ЕГО ОСНОВЕ
US20100105875A1 (en) * 2008-06-09 2010-04-29 Maria Scarselli Antibodies against neisserial factor H binding protein
JP5487463B2 (ja) * 2008-08-08 2014-05-07 独立行政法人産業技術総合研究所 非拡散植物ウイルスベクター
HUE049695T2 (hu) 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
CA2765112A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
WO2011008400A2 (en) 2009-06-16 2011-01-20 Novartis Ag High-throughput complement-mediated antibody-dependent and opsonic bactericidal assays
US20110076300A1 (en) 2009-08-27 2011-03-31 Mariagrazia Pizza Hybrid Polypeptides Including Meningococcal fHBP Sequences
ES2443952T3 (es) 2009-09-02 2014-02-21 Novartis Ag Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
CN102724988B (zh) 2009-09-30 2014-09-10 诺华股份有限公司 脑膜炎球菌fHBP多肽的表达
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
SG10201501980SA (en) 2009-12-15 2015-05-28 Novartis Ag Homogeneous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
CA2803239A1 (en) 2010-06-25 2011-12-29 Novartis Ag Combinations of meningococcal factor h binding proteins
KR101594228B1 (ko) 2010-08-23 2016-02-15 와이어쓰 엘엘씨 네이세리아 메닌기티디스 ｒＬＰ２０８６ 항원의 안정한 제제
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
BR112013005626B1 (pt) 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
CA2846290A1 (en) 2011-08-31 2013-03-07 Children's Hospital & Research Center Oakland Engineered sequences to facilitate expression of antigens in neisseria and methods of use
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
MX359256B (es) 2012-03-09 2018-09-19 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
MX357538B (es) 2012-06-14 2018-07-13 Novartis Ag Vacunas para meningococo de serogrupo x.
AU2013295242C1 (en) 2012-07-27 2018-08-09 Institut National De La Sante Et De La Recherche Medicale CD147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014084432A1 (ko) * 2012-11-30 2014-06-05 경상대학교 산학협력단 헬리코박터 파일로리 발현 벡터
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
JP6786394B2 (ja) 2014-02-28 2020-11-18 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 改変髄膜炎菌ｆＨｂｐポリペプチド
CA3212723A1 (en) 2014-07-23 2016-01-28 Peter T. Beernink Factor h binding protein variants and methods of use thereof
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
GB201522153D0 (en) 2015-12-15 2016-01-27 Univ Southampton Meningococcal infection and modified neisseria lactamica
US12161707B2 (en) 2016-09-02 2024-12-10 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
EP3312192B1 (en) * 2016-10-24 2023-02-22 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles
AU2018215585B2 (en) 2017-01-31 2022-03-17 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN110516550B (zh) * 2019-07-26 2022-07-05 电子科技大学 一种基于fpga的车道线实时检测方法
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7825273B2 (ja) * 2019-11-25 2026-03-06 グリフィス ユニバーシティー 淋菌感染症に対する免疫原性タンパク質
US12053516B2 (en) 2021-02-19 2024-08-06 Sanofi Pasteur Inc. Meningococcal B recombinant vaccine
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2026072910A1 (en) 2024-09-27 2026-04-02 Sanofi Pasteur Inc. Anti-meningococcal antibodies for in vitro immunoassay

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239749A (en) * 1979-09-27 1980-12-16 United States Of America Neisseria gonorrhoeae vaccine
CA1282721C (en) 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
US5288641A (en) * 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
EP0273116A3 (en) 1986-10-09 1990-05-02 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Gonococcal and meningococcal polypeptides, vaccines and diagnostics
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5270176A (en) * 1987-11-20 1993-12-14 Hoechst Aktiengesellschaft Method for the selective cleavage of fusion proteins with lysostaphin
CA1340506C (en) * 1987-11-24 1999-04-20 Nicholas H. Carbonetti Production of gonorrheal pi proteins and vaccines
WO1989009271A1 (en) 1988-03-21 1989-10-05 Viagene, Inc. Recombinant retroviruses
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
NL8803111A (nl) 1988-12-19 1990-07-16 Nederlanden Staat Multivalent meningococcen klasse i buitenmembraaneiwit vaccin.
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es) 1989-03-21 1998-07-16 Vical Inc Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
GB8919607D0 (en) 1989-08-30 1989-10-11 Wellcome Found Novel entities for cancer therapy
CU22302A1 (es) 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
IE912559A1 (en) 1990-07-19 1992-01-29 Merck & Co Inc The class ii protein of the outer membrane of neisseria¹meningitidis, and vaccines containing same
EP1285967A3 (en) 1990-09-21 2005-03-02 Chiron Corporation Human retroviral packaging cell line
US5965424A (en) * 1991-01-11 1999-10-12 Boehringer Mannheim Gmbh Methods for making neisseria or hemophilus IgA protease and DNA encoding the proteases
JP3213313B2 (ja) * 1991-03-14 2001-10-02 イムクローン システムズ インコーポレーテッド 組み換えハイブリッドポーリンエピトープ
FR2681786A1 (fr) 1991-09-27 1993-04-02 Centre Nat Rech Scient Vecteurs recombinants d'origine virale, leur procede d'obtention et leur utilisation pour l'expression de polypeptides dans des cellules musculaires.
IL103059A0 (en) 1991-09-30 1993-02-21 Boehringer Ingelheim Int Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6100380A (en) * 1991-10-28 2000-08-08 Cytran, Inc. Immunomodulating peptides and methods of use
WO1993014778A1 (en) 1992-01-23 1993-08-05 Vical, Inc. Ex vivo gene transfer
FR2692592B1 (fr) * 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
CA2139847C (en) * 1992-07-07 2002-05-21 Akio Matsuhisa Probe for diagnosing infectious disease
US6592873B1 (en) 1992-10-30 2003-07-15 Iowa State University Research Foundation, Inc. Polynucleic acids isolated from a porcine reproductive and respiratory syndrome virus (PRRSV) and proteins encoded by the polynucleic acids
DE69415462T2 (de) * 1993-01-23 1999-07-15 Inmunologia Y Genetica Aplicada, S.A., Madrid Synthetischen peptiden und impfstoffe gegen parvovirus
US5439808A (en) 1993-07-23 1995-08-08 North American Vaccine, Inc. Method for the high level expression, purification and refolding of the outer membrane group B porin proteins from Neisseria meningitidis
AU7408494A (en) * 1993-07-30 1995-02-28 University Of North Carolina At Chapel Hill, The Production of gonorrheal pi proteins and vaccines in e. coli and salmonella
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
US5510264A (en) 1993-09-28 1996-04-23 Insight Biotech Inc. Antibodies which bind meningitis related homologous antigenic sequences
PT729351E (pt) 1993-11-16 2000-12-29 Skyepharma Inc Vesiculas com libertacao controlada de activos
WO1995030763A2 (en) 1994-05-09 1995-11-16 Chiron Viagene, Inc. Retroviral vectors having a reduced recombination rate
FR2720408B1 (fr) * 1994-05-31 1996-08-14 Pasteur Merieux Serums Vacc Fragments Tbp2 de Neisseria meningitidis.
US6245337B1 (en) 1994-08-25 2001-06-12 Washington University Haemophilus adherence and penetration proteins
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US5646259A (en) 1995-03-24 1997-07-08 St. Louis University DNA encoding haemophilus adhesion proteins
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
ATE339436T1 (de) * 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
IL123720A (en) 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
DE19534579C2 (de) 1995-09-18 2000-06-08 Max Planck Gesellschaft Nucleinsäure-Moleküle codierend Proteine, die die Adhäsion von Neisseria-Zellen an humane Zellen vermitteln
FR2739624B1 (fr) * 1995-10-10 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle sous-unite tbp2 de neisseria meningitidis
ZA9610456B (en) * 1995-12-20 1997-06-20 Novo Nordisk As N-terminally extended proteins expressed in yeast
HUP9901039A2 (hu) 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US6083499A (en) * 1996-04-19 2000-07-04 Mycogen Corporation Pesticidal toxins
AU5426098A (en) 1996-10-24 1998-05-15 Emory University Invasion associated genes from (neisseria meningitidis) serogroup
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100615109B1 (ko) 1996-12-20 2006-08-22 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 모렉셀라 카타르할리스의 ｕｓｐａ1, ｕｓｐａ2 항원
US6017531A (en) 1997-06-02 2000-01-25 W. R. Grace & Co. Hydrophilic composition containing protease produced by Vibrio
US6583275B1 (en) * 1997-07-02 2003-06-24 Genome Therapeutics Corporation Nucleic acid sequences and expression system relating to Enterococcus faecium for diagnostics and therapeutics
CN1263854C (zh) * 1997-11-06 2006-07-12 启龙股份公司 奈瑟球菌抗原
US6914131B1 (en) * 1998-10-09 2005-07-05 Chiron S.R.L. Neisserial antigens
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) * 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
DK1053329T3 (da) * 1998-02-03 2010-01-25 Ct Disease Contr & Prevention Rekombinant lipideret PsaA-protein, fremgangsmåder til fremstilling og anvendelse
HRP20000537A2 (en) * 1998-02-11 2000-10-31 Lilly Co Eli Processes and intermediates useful to make antifolates
GB9808734D0 (en) 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
US6150502A (en) * 1998-04-29 2000-11-21 Genesis Research & Development Corporation Limited Polypeptides expressed in skin cells
EP2261352A3 (en) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
US20070026021A1 (en) * 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
US6615024B1 (en) * 1998-05-01 2003-09-02 Arraycomm, Inc. Method and apparatus for determining signatures for calibrating a communication station having an antenna array
US5990085A (en) * 1998-05-04 1999-11-23 Michigan State University Inhibin-HBc fusion protein
GB9810276D0 (en) 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
BR9914374A (pt) * 1998-10-09 2002-09-17 Chiron Corp Sequências genÈmicas de neisseria e métodos para seu uso
CA2359486A1 (en) 1999-01-15 2000-07-20 Smithkline Beecham Biologicals S.A. Neisseria meningitidis polypeptide basb052
CA2360658A1 (en) 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
GB9902084D0 (en) 1999-01-29 1999-03-24 Smithkline Beecham Biolog Novel compounds
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
JP2003518363A (ja) * 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
CN101033467A (zh) 1999-04-30 2007-09-12 希龙公司 奈瑟球菌基因组序列及其用法
EP2270173B1 (en) * 1999-05-19 2016-01-06 GlaxoSmithKline Biologicals SA Combination neisserial compositions
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
RU2281956C2 (ru) * 1999-10-29 2006-08-20 Чирон С.Р.Л. Антигенные пептиды neisseria
CA2390344C (en) * 1999-11-29 2014-08-26 Chiron Spa 85kda neisserial antigen
GB9928676D0 (en) 1999-12-03 2000-02-02 Provalis Uk Ltd Pseudomonas aeruginosa antigens
US20010031268A1 (en) * 1999-12-17 2001-10-18 Baldwin Thomas John Antigen preparations
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
PL216780B1 (pl) 2000-01-25 2014-05-30 Univ Queensland Of Santa Lucia Wyizolowane białka zawierające konserwatywne obszary antygenu powierzchniowego NhhA z Neisseria meningitidis, białka fuzyjne, kompozycja farmaceutyczna, przeciwciało monoklonalne lub wiążący antygen fragment przeciwciała monoklonalnego, wyizolowany kwas nukleinowy, konstrukt ekspresyjny, komórka gospodarza, sposób wytwarzania rekombinowanego białka, sposób wykrywania N. meningitidis w próbce biologicznej, sposób diagnozowania zakażenia N. meningitidis oraz sposób wykrywania N. meningitidis w próbce biologicznej uzyskanej od pacjenta oraz zastosowanie wyizolowanego białka, białka fuzyjnego i konstruktu ekspresyjnego
ES2281409T3 (es) * 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
CA2407352A1 (en) 2000-04-21 2001-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of acne vulgaris
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
GB0017149D0 (en) 2000-07-12 2000-08-30 Chiron Spa Helicobacter pylori mutants
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20040073294A1 (en) * 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
GB0103424D0 (en) * 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
CA2452720C (en) 2001-07-26 2012-04-17 Chiron S.R.L. Vaccines comprising aluminium adjuvants and histidine
GB0118249D0 (en) * 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
BR0211494A (pt) * 2001-07-27 2004-08-17 Chiron Srl Adesinas de meningococo nada, app e orf 40
MX339524B (es) * 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0129007D0 (en) * 2001-12-04 2002-01-23 Chiron Spa Adjuvanted antigenic meningococcal compositions
EP1524991A1 (en) * 2002-08-02 2005-04-27 GlaxoSmithKline Biologicals S.A. Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
US7785608B2 (en) * 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
HUE031886T2 (en) * 2002-10-11 2017-08-28 Glaxosmithkline Biologicals Sa Polypeptide vaccines for extensive protection against hypervirulent meningococcal lines
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
CA2512917A1 (en) 2003-01-15 2004-08-05 Wyeth Holdings Corporation Methods for increasing neisseria protein expression
ES2461350T3 (es) * 2003-01-30 2014-05-19 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
MXPA05011110A (es) 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
GB0315021D0 (en) * 2003-06-26 2003-07-30 Chiron Srl Immunogenic gonococcal compositions
GB0323103D0 (en) * 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CN103357002A (zh) * 2003-10-02 2013-10-23 诺华疫苗和诊断有限公司 多种脑膜炎球菌血清群的液体疫苗
GB0408977D0 (en) * 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0409748D0 (en) * 2004-04-30 2004-06-09 Chiron Srl Lactoferrin cleavage
GB0410866D0 (en) * 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
ES2616294T3 (es) 2005-01-27 2017-06-12 Children's Hospital & Research Center At Oakland Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
PL2004225T3 (pl) 2006-03-22 2012-09-28 Novartis Ag Schematy immunizacji koniugatami meningokokowymi
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
CA2656474A1 (en) * 2006-06-29 2008-01-03 Novartis Ag Polypeptides from neisseria meningitidis
AR064642A1 (es) * 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
WO2008125985A2 (en) 2007-04-11 2008-10-23 Novartis Ag Blocking interaction between pathogen factors and factor h to inhibit hemorrhagic syndromes
CA2688268A1 (en) 2007-06-04 2008-12-11 Novartis Ag Formulation of meningitis vaccines
CN102356089B (zh) 2008-02-21 2014-02-19 诺华股份有限公司 脑膜炎球菌fHBP多肽
PT2268618E (pt) * 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland Proteínas quiméricas de unión al factor H (fHBP) que contienen un dominio B heterólogo, y métodos de uso
WO2010028096A2 (en) 2008-09-03 2010-03-11 Children's Hospital & Research Center At Oakland Peptides presenting an epitope of an a domain of factor h binding protein and methods of use
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
HUE049695T2 (hu) * 2009-03-24 2020-10-28 Glaxosmithkline Biologicals Sa Adjuváló H meningococcus faktort kötõ fehérje
ES2458355T3 (es) * 2010-09-01 2014-05-05 Novartis Ag Adsorción de inmunopotenciadores sobre sales metálicas insolubles
ES2744471T3 (es) * 2010-09-04 2020-02-25 Glaxosmithkline Biologicals Sa Ensayos de anticuerpos bactericidas para evaluar la inmunogenia y la potencia de vacunas de sacárido capsular meningocócico
BR112013005626B1 (pt) * 2010-09-10 2022-07-26 Glaxosmithkline Biologicals Sa Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição
CN103648489A (zh) * 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
US9184727B2 (en) * 2012-06-11 2015-11-10 Phonon Corporation SAW device and method for post-seal frequency trimming

Also Published As

Publication number Publication date
CN101906413A (zh) 2010-12-08
US9267163B2 (en) 2016-02-23
US20130005667A1 (en) 2013-01-03
HK1055993A1 (zh) 2004-01-30
EP2270030A2 (en) 2011-01-05
EP1947187B1 (en) 2011-03-30
DE60144353D1 (de) 2011-05-12
NZ521396A (en) 2004-06-25
AU3948801A (en) 2001-09-12
CA2744921A1 (en) 2001-09-07
PT2270030E (pt) 2012-07-24
CA2875231A1 (en) 2001-09-07
HK1064120A1 (zh) 2005-01-21
CY1106532T1 (el) 2012-01-25
US7803387B2 (en) 2010-09-28
WO2001064920A2 (en) 2001-09-07
US20060051840A1 (en) 2006-03-09
DK1261723T3 (da) 2008-06-23
US20040092711A1 (en) 2004-05-13
JP2014000092A (ja) 2014-01-09
EP1790660B1 (en) 2012-06-20
JP4763210B2 (ja) 2011-08-31
RU2299906C2 (ru) 2007-05-27
JP2011083287A (ja) 2011-04-28
CY2013025I1 (el) 2015-11-04
JP4846160B2 (ja) 2011-12-28
DK2270030T3 (da) 2012-08-13
CA2400570C (en) 2010-04-27
BR0108711A (pt) 2004-06-22
US20100267931A1 (en) 2010-10-21
ATE387502T1 (de) 2008-03-15
JP5346004B2 (ja) 2013-11-20
CN1201011C (zh) 2005-05-11
JP2016128520A (ja) 2016-07-14
CY1111591T1 (el) 2015-10-07
AU3947801A (en) 2001-09-12
CA2400570A1 (en) 2001-09-07
JP2011101657A (ja) 2011-05-26
JP2003525049A (ja) 2003-08-26
CN101139590A (zh) 2008-03-12
DE60132978D1 (de) 2008-04-10
EP2270031A3 (en) 2011-02-16
CY1113032T1 (el) 2016-04-13
CN101139590B (zh) 2012-07-18
PT1790660E (pt) 2012-09-17
DK1947187T3 (da) 2011-05-09
US8703914B2 (en) 2014-04-22
RU2002125882A (ru) 2004-03-10
CA2400562C (en) 2011-09-20
EP2270030B1 (en) 2012-05-23
EP1790660A2 (en) 2007-05-30
CN1800385B (zh) 2010-06-02
EP1259627A2 (en) 2002-11-27
CA2400562A1 (en) 2001-09-07
CY1107447T1 (el) 2012-12-19
CA2689666A1 (en) 2001-09-07
CN1508253A (zh) 2004-06-30
EP1947187A1 (en) 2008-07-23
EP1259627B1 (en) 2007-01-24
RU2002125880A (ru) 2004-03-10
AU2001239478B2 (en) 2007-05-17
DE60126249D1 (de) 2007-03-15
CN1544462A (zh) 2004-11-10
US20170080077A1 (en) 2017-03-23
WO2001064920A3 (en) 2002-03-14
ES2360746T9 (es) 2012-02-13
CN1426473A (zh) 2003-06-25
ES2299476T3 (es) 2008-06-01
HK1056197A1 (en) 2004-02-06
NL300605I2 (https=) 2016-09-22
MXPA02008313A (es) 2002-12-09
EP1947187B9 (en) 2011-09-21
US9150898B2 (en) 2015-10-06
AU2001239488B2 (en) 2006-01-19
CA2689666C (en) 2015-02-24
EP1790660A3 (en) 2007-10-31
JP2013005816A (ja) 2013-01-10
ATE503837T1 (de) 2011-04-15
DE60132978T2 (de) 2009-02-26
JP5941027B2 (ja) 2016-06-29
CN1800385A (zh) 2006-07-12
CN100334214C (zh) 2007-08-29
US20170080076A1 (en) 2017-03-23
ES2391153T3 (es) 2012-11-22
CN1426471A (zh) 2003-06-25
US8114960B2 (en) 2012-02-14
WO2001064922A3 (en) 2001-12-06
CA2744921C (en) 2014-05-13
DK1790660T3 (da) 2012-09-17
EP1261723B1 (en) 2008-02-27
HK1071147A1 (zh) 2005-07-08
CN100473663C (zh) 2009-04-01
ES2386534T3 (es) 2012-08-22
US20140363462A1 (en) 2014-12-11
CY1113477T1 (el) 2016-06-22
US20040110670A1 (en) 2004-06-10
BR0108713A (pt) 2004-06-22
US20140294885A1 (en) 2014-10-02
WO2001064922A2 (en) 2001-09-07
EP1261723A2 (en) 2002-12-04
NZ521531A (en) 2005-12-23
CY2013025I2 (el) 2015-11-04
EP2270030A3 (en) 2011-02-02
EP2270031A2 (en) 2011-01-05
PT1947187E (pt) 2011-07-04
MXPA02008314A (es) 2002-12-09
ATE352631T1 (de) 2007-02-15
DK1947187T5 (da) 2011-10-24
CN100339482C (zh) 2007-09-26
JP2003525050A (ja) 2003-08-26
DE60126249T2 (de) 2008-05-29
JP2014121333A (ja) 2014-07-03
LU92240I2 (fr) 2013-09-04
ES2360746T3 (es) 2011-06-08
PT1261723E (pt) 2008-06-05
RU2304617C2 (ru) 2007-08-20

Similar Documents

Publication Publication Date Title
ES2281409T3 (es) Expresion heterologa de proteinas de neisseria.
ES2278436T3 (es) Antigenos de estreptococos del grupo b.
AU2001239478A1 (en) Hybrid expression of neisserial proteins
JP5209163B2 (ja) Ｐ．ｇｉｎｇｉｖａｌｉｓ抗原組成物
TW201021845A (en) Prevention, treatment and diagnosis of P. gingivalis infection
JP3440221B2 (ja) アクチノバチルス・プレウロニウモニアからのタンパク質
JP4358909B2 (ja) 歯周炎の診断および治療用のポルフィロモナス・ジンジバリス抗原
PL199497B1 (pl) Wyizolowany polipeptyd, jego immunogenny fragment, wyizolowany polinukleotyd, wektor ekspresyjny, komórka gospodarza, błona komórki gospodarza, sposób wytwarzania polipeptydu lub immunogennego fragmentu, sposób wyrażania polinukleotydu, kompozycja szczepionki, przeciwciało, zastosowanie kompozycji zawierającej polipeptyd, zastosowanie kompozycji zawierającej polinukleotyd, kompozycja terapeutyczna oraz sposób diagnozowania zakażenia Moraxella catarrhalis
Han Development of a DNA vaccine against Streptococcus mutans: A novel approach to immunization against dental caries
HK1064120B (en) Hybrid expression of neisserial proteins